ASCO 2026: Updates in bladder cancer

ASCO 2026: Updates in testicular, germ cell and rare genitourinary cancer

First-in-class switchable allogeneic CAR-T therapy shows promising activity in relapsed or refractory AML

Epcoritamab plus rituximab and lenalidomide improves outcomes across follicular lymphoma subgroups

Epcoritamab improves progression-free survival in relapsed or refractory large B-cell lymphoma

First-in-human study of in vivo CAR-T therapy shows promising activity in relapsed or refractory B-cell non-Hodgkin lymphoma

CD19 CD22 bispecific CAR T cell therapy achieves high response rates in R/R large B cell lymphoma

Subcutaneous blinatumomab plus TKI drives high remission in relapsed Ph+ acute lymphoblastic leukaemia

Surovatamig plus rituximab induces high complete response rates in previously untreated follicular lymphoma

Romiplostim thrombopoietin receptor agonist rapidly restores platelet counts in acute ITP in 1L treatment during COVID 19

Tafasitamab plus lenalidomide added to R-CHOP improves PFS in high-risk diffuse large B-cell lymphoma

ASCO 2026: Breast cancer overview